CAR T-cell Therapy | Specialty

The car t-cell therapy condition center is a comprehensive resource for clinical news and expert insights on car t-cell therapy. Read more at OncLive.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies

June 18th 2025

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

June 17th 2025

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma

June 16th 2025

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.

ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.

Anito-Cel Drives Durable Responses in R/R Multiple Myeloma

June 14th 2025

Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

June 3rd 2025

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC

June 2nd 2025

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Dr Farid on the Clinical Utility of Tabelecleucel in R/R EV+ PTLD

May 29th 2025

Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The Move From Blood to Solid: Open Opportunities for CAR T-Cell Therapy in Solid Tumors

May 22nd 2025

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

Allogeneic CAR T-Cell Therapy CT0596 Yields Preliminary Efficacy and Safety in R/R Myeloma

May 12th 2025

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

Retrospective Data Show Improved Efficacy but Higher Toxicity With Cilta-Cel vs Ide-Cel in R/R Myeloma

April 24th 2025

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Dr Ahmed on the Safety Profile of NKTR-255 in Relapsed/Refractory LBCL

April 23rd 2025

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Inati-Cel Induces High CR and MRD Negativity Rates in CD19+ R/R B-ALL

April 23rd 2025

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Garfall on the Rationale of the Phase 2 BMT CTN 1902 Trial in Myeloma

April 21st 2025

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Dr Ip on Reasons for Studying Real-World CAR T-Cell Therapy Outcomes in LBCL

April 21st 2025

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Dr Bishop on the Rationale for Evaluating Anito-Cel in R/R Myeloma

April 21st 2025

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies

April 21st 2025

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

x